Keros Therapeutics, Inc.(KROS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,586 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in KROS
Events flagged as statistical outliers against KROS's own multi-year baseline — not fixed dollar thresholds.
- Score shock2026-08-06
KROS quality score dropped 33 points (57→24) on a new filing
View source filing →
KROS Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Keros Therapeutics, Inc. (KROS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KROS at 27.3/100 on a 32-signal composite quality model, placing it at rank #2,586 of 2,962 stocks — the bottom half of the AI-ranked universe. KROS scores in the top quartile across revenue growth (99.3). Areas of concern include revenue scale (2.9) and profitability (3.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 14.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Keros Therapeutics, Inc. reports net income of $-28.7M, free cash flow of $-20.6M. Top institutional holders of KROS by reported 13-F value include BlackRock, Nantahala Capital Management, AQR CAPITAL MANAGEMENT, based on the most recent SEC filings. KROS trades on the Nasdaq exchange and files with the SEC under CIK 1664710. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KROS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Keros Therapeutics, Inc. directly from SEC EDGAR. Keros Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 4 and 74 since 2022, currently 27.3 — an improving long-term trajectory across 60 quarterly and live scoring snapshots.
Revenue
Q2 2026
$0.00
Net Income
Q2 2026
$-28.7M
Free Cash Flow
Q2 2026
$-20.6M
ROIC
Q2 2026
-47.2%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
+146.4% YoYOperating Income
+132.0% YoYEPS (Diluted)
+146.0% YoYTotal Assets
-45.1% YoYOp. Cash Flow
+166.8% YoYFree Cash Flow
+165.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $243.9M | $0.00 -100.0% | $151.0K | $0.00 -100.0% | $20.1M | $0.00 |
| Net Income | $87.0M +146.4% | $-187.4M -22.5% | $-153.0M -46.2% | $-104.7M -78.2% | $-58.7M -29.5% | $-45.4M |
| Operating Income | $67.6M +132.0% | $-210.8M -24.1% | $-169.9M -48.0% | $-114.8M -103.6% | $-56.4M -20.8% | $-46.7M |
| EPS (Diluted) | $2.30 +146.0% | $-5.00 +3.8% | $-5.20 -25.3% | $-4.15 -64.7% | $-2.52 +14.0% | $-2.93 |
| Total Assets | $338.0M -45.1% | $615.9M +66.4% | $370.0M +20.6% | $306.8M +20.2% | $255.3M -5.3% | $269.4M |
| Operating Cash Flow | $107.5M +166.8% | $-160.9M -29.2% | $-124.5M -77.7% | $-70.1M -12.7% | $-62.1M -68.5% | $-36.9M |
| Free Cash Flow | $106.0M +165.1% | $-162.8M -28.2% | $-127.0M -78.1% | $-71.3M -12.9% | $-63.2M -69.9% | $-37.2M |
Get alerted when KROS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Keros Therapeutics, Inc. including:
Top Institutional Holders of KROS
BlackRock, Inc.
$29.9M2,794,217 shNantahala Capital Management, LLC
$15.1M1,410,419 shAQR CAPITAL MANAGEMENT LLC
$10.4M967,859 shVANGUARD CAPITAL MANAGEMENT LLC
$8.9M833,596 shORBIMED ADVISORS LLC
$8.1M759,155 shFEDERATED HERMES, INC.
$7.5M700,427 shVANGUARD PORTFOLIO MANAGEMENT LLC
$7.0M652,635 shMACKENZIE FINANCIAL CORP
$6.7M628,438 shMadison Avenue Partners, LP
$6.7M626,583 shQube Research & Technologies Ltd
$6.5M608,837 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $29.9M | 2,794,217 |
| Nantahala Capital Management, LLC | $15.1M | 1,410,419 |
| AQR CAPITAL MANAGEMENT LLC | $10.4M | 967,859 |
| VANGUARD CAPITAL MANAGEMENT LLC | $8.9M | 833,596 |
| ORBIMED ADVISORS LLC | $8.1M | 759,155 |
| FEDERATED HERMES, INC. | $7.5M | 700,427 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $7.0M | 652,635 |
| MACKENZIE FINANCIAL CORP | $6.7M | 628,438 |
| Madison Avenue Partners, LP | $6.7M | 626,583 |
| Qube Research & Technologies Ltd | $6.5M | 608,837 |
Companies Similar to KROS
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
ENANTA PHARMACEUTICALS INC
Centessa Pharmaceuticals plc
IDEAYA Biosciences, Inc.
Arcturus Therapeutics Holdings Inc.
uniQure N.V.
Arbutus Biopharma Corp
Janux Therapeutics, Inc.
Xencor Inc
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put KROS on your watchlist
Track score changes the day Keros Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is KROS a good stock to buy?
13F Pro's AI-powered analysis of Keros Therapeutics, Inc. (KROS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KROS are available on the KROS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. KROS is classified as a small company.
Which hedge funds own KROS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KROS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Keros Therapeutics, Inc.'s investment landscape.